Hair Loss Drugs: Alopecia Areata and Androgenetic Alopecia
As of 2026-11-14, Lilly’s Olumiant, Pfizer’s Litfulo and India’s Sun Pharma Leqselvi had US alopecia areata approvals; AnHorn’s AH-001 belongs to the separate AGA development field.
Lilly reported on 2026-09-25 that 42% on Olumiant 4 mg versus 5% on placebo reached SALT ≤20 at Week 36 in adolescent alopecia areata.
Nektar said on 2026-11-12 that its rezpegaldesleukin AA Phase 3 was planned to begin in December 2026; initiation and design are the next test beyond JAK inhibition.
Alopecia areata (AA) is immune-mediated; androgenetic alopecia (AGA) involves androgen signaling. The two populations are grouped separately and their hair outcomes are not interchangeable.
Competitive landscape
| Asset | Company | Mechanism / route | Stage | Indication | Trial identifier | Deal | Latest development | Source |
|---|---|---|---|---|---|---|---|---|
| Olumiant / baricitinib | Eli LillyUS | JAK1/2 inhibitorOral | US approved | AA; age 12+ | — | — | Adolescent Week 36 SALT ≤20: 42% with 4 mg | lilly.gcs-web.compi.lilly.com |
| Litfulo / ritlecitinib | PfizerUS | JAK3 / TEC-family inhibitorOral | US approved | Severe AA; age 12+ | — | — | FDA pivotal evidence: 718 patients | fda.gov |
| Leqselvi / deuruxolitinib | Sun PharmaIndia | JAK inhibitorOral | US approved | Adult severe AA | — | — | FDA original approval 2024-07-25; approval is distinct from supply | fda.gov |
| rezpegaldesleukin | NektarUS | IL-2 / regulatory T-cell pathwaySubcutaneous | Post-Phase 2 AA; Phase 3 planned | AA | — | — | AA Phase 3 planned December 2026; distinct from AD Phase 3 | prnewswire.com |
| AH-001 | AnHorn MedicinesTaiwan | AR protein degradationTopical | US Phase 1 completion announced | AGA | — | — | Phase 1 completed per 2025-10-30 release; Phase 2 efficacy testing next, no date verified | anhornmed.com |
| GT20029 | Kintor PharmaChina | AR protein degradationTopical | Historical Phase 2 results reported | AGA | — | — | Positive Phase 2 release dated 2024-04-21; current stage not inferred | en.kintor.com.cn |
Taiwan and Asia
Taiwan’s AnHorn announced US Phase 1 completion for topical AR degrader AH-001 on 2025-10-30; safety findings do not establish hair-growth efficacy. China’s Kintor reported positive AGA Phase 2 results for GT20029 on 2024-04-21; this is dated historical evidence, without an assumed Phase 3 outcome. India’s Sun Pharma has an approved AA drug, a different indication.